Protocol 2: tirzepatide microdose for autoimmune inflammation Goal: Leverage dual GIP/GLP-1 receptor activation for broader anti-inflammatory coverage Starting dose: 0.5 mg tirzepatide subcutaneously, once weekly Week 1 to 6: Hold at 0.5 mg
They have various indications, including managing blood sugar in people with type 2 diabetes and helping with weight management
GLP-1 and the Future of Nutrition: Innovations in AI and Tech Outside of retail, in todays AI and digital era, the impact of GLP-1 extends to businesses integrating digital solutions into nutrition and health
They work through appetite and metabolic pathways, not by directly altering estrogen, progesterone, or testosterone levels
And it is exactly the kind of practical detail that separates researchers who get consistent results from those who wonder why their protocol feels different every week
A structured monitoring approach transforms the treatment duration question from anxiety-inducing uncertainty into evidence-based decision-making
